Board of Directors

Peter Devlin , Chairman of the Board & Compensation Chairman

Peter Devlin has served as a member of our board of directors since April 2016. From August 2009 to September 2014, Mr. Devlin was the chief commercial officer at Insulet Corporation, a manufacturer of diabetes insulin device products, where he was responsible for the company’s worldwide commercial operations. Prior to joining Insulet, Mr. Devlin held several leadership roles at Abbott Laboratories, Inc. From February 2008 to July 2009, he served as divisional vice president of Abbott’s Global Strategic Marketing in the diabetes care unit, prior to which he served as general manager, hospital & government in the diabetes care unit from December 2006 to February 2008, and prior to which he served as director of Abbott’s Canadian diabetes unit from September 2003 to December 2006. Mr. Devlin received his Bachelor of Science degree from the University of Massachusetts. Mr. Devlin is qualified to serve as a director because of his extensive business experience in the field of diabetes.

Rodney D. Altman , M.D. , Member

Rodney Altman, M.D. has been a director since April 2016. As an advisor to BDC Ventures he serves as a board director to Milestone Pharmaceuticals. Dr. Altman is an independent board director at Siris Medical and a Managing Director at Spindletop Capital. From 2013 through 2016, he had an operating role at Team Health (TMH), a healthcare provider outsourcing company. From 2006-2011, Dr. Altman was a senior partner at CMEA Capital where he built and managed the firm’s medical device practice. Prior to that, Dr. Altman was a Co-Founder and Managing Director of Aphelion Capital. He also worked at Piper Jaffray Ventures and was a Partner at TVM Techno Venture Management. Dr. Altman has been practicing emergency medicine for over 25 years. Today, he continues to work in emergency medicine part-time at Stanford University Medical Center, where he is a Clinical Assistant Professor of Emergency Medicine in the Department of Surgery. Dr. Altman received his MD degree from McGill University and an MBA degree from the University of Chicago.

Katherine D. Crothall , Ph.D. , Member

Katherine D. Crothall, Ph.D. has served as a member of our board of directors since October 2016. Dr. Crothall currently serves as President, Chief Executive Officer, and Chairman of the Board of Aspire Bariatrics, a company committed to providing safe and effective treatments for obesity to patients worldwide. Prior to Aspire, Dr. Crothall was a Principal at Liberty Venture Partners, a venture capital firm located in Philadelphia, from 2006 until November 2010. Prior to Liberty, Dr. Crothall was Founder, President, and Chief Executive Officer of Animas Corporation, a leading manufacturer of insulin infusion pumps located in West Chester, PA, from its inception to its acquisition by Johnson & Johnson Corporation in February 2006. Prior to Animas, Dr. Crothall was also the Founder, President and Chief Executive Officer of two other medical device companies: Luxar Corporation, founded in 1988 and sold to ESC Medical, and Laakmann Electro-Optics, founded in 1978 and sold to Johnson & Johnson in 1981. Dr. Crothall continued running Laakmann Electro-Optics for five years post-acquisition.

Dr. Crothall received her B.S. from University of Pennsylvania and her Ph.D. from University of Southern California, both in Electrical Engineering. She holds over 20 patents and is the recipient of several awards including the Ernst & Young Entrepreneur of the Year Award in 2003 and the Greater Philadelphia Raymond Rafferty Entrepreneurial Excellence Award in 2004. Dr. Crothall is a director of Adhezion BioMedical and Xanitos, Inc. She also sits on the Board of Overseers of the School of Engineering and Applied Sciences at the University of Pennsylvania.

Luke Düster has served as a member of our board of directors since January 2016. Since 2009, Mr. Düster has worked for CRG investing in healthcare companies across a wide range of product technologies and therapeutic areas. Prior to joining Capital Royalty Group L.P., Mr. Düster was at Harris Williams & Co. from 2004 to 2009, where he served as vice president and advised private equity and corporate clients across a broad range of M&A assignments. Mr. Düster also held investment banking roles at the Wallach Company a regional investment banking boutique, from 2000 to 2002, and the Nord Companies, a healthcare advisory firm, from 1998 to 2000. Mr. Düster received his B.S. summa cum laude from the University of Colorado at Boulder and an M.B.A. with honors from the Wharton School of the University of Pennsylvania. Mr. Düster is qualified to serve as a director because of his significant experience working with companies backed by private equity investors, particularly in the healthcare industry, as well as his experience with healthcare investing.

Brian Roberts , Audit Chairman

Brian Roberts has served as a member of our board of directors since July 2016. Mr. Roberts most recently served as the chief operating and financial officer of Avedro, Inc. He also currently serves on the board of directors of ViewRay, where he is chairman of the audit committee. Prior to Avedro, he served as CFO for Insulet Corporation, a tubeless insulin pump technology company. Under his supervision, Insulet grew from approximately $30 million to nearly $300 million in revenue, achieved operating profitability and increased its market capitalization to over $2 billion. Previously, Mr. Roberts served as CFO for Jingle Networks, a leader in mobile voice-ad services that was acquired by Marchex, and as CFO for Digitas, which was sold for $1.3 billion to Publicis Groupe. He holds a Bachelor of Science in accounting and finance from Boston College, is a certified public accountant, and served as an auditor with Ernst & Young LLP.

John Timberlake , President & Chief Executive Officer

John Timberlake has served as our chief executive officer, president and chief commercial officer and a member of our board of directors since February 2016, prior to which he served as president and chief commercial officer since August 2008. Before becoming chief executive officer, president and chief commercial officer, Mr. Timberlake was a general manager with our company from September 2006 to August 2008. Prior to joining Valeritas, Mr. Timberlake held positions of increasing responsibility from 1991 to 2006 at Sanofi-Aventis (now Sanofi), with his last role as vice president of diabetes marketing, where he was responsible for the diabetes franchise, including the brands Lantus, Apidra and Amaryl. While at Sanofi, Mr. Timberlake had extensive experience and commercial responsibilities for new products in development across multiple therapeutic areas, including inhaled insulin and other metabolic products. Prior to working in the healthcare industry, Mr. Timberlake was a manager with Deloitte & Touche LLP from 1986 to 1991 and was both a certified management accountant and a certified public accountant. He earned a B.S. in accounting at Northwest Missouri State University, an M.S. in management from Purdue University and an MBA from ESC Rouen in France (now NEOMA Business School).

Joe Mandato , D.M. , Member

Joe Mandato, D.M., has served as a member of our board of directors since December 2016. Beginning in March, 2003, Dr. Mandato has been a Managing Director at De Novo Ventures, a venture capital firm focused on the life sciences. Dr. Mandato also serves as a Senior Advisor to Mainsail Partners and its portfolio companies. Dr. Mandato served as a member of the Board of Directors of AxoGen Corporation from February 2006 until its merger with and into AxoGen, Inc. in September 2011, and then served on the Board of AxoGen, Inc. until September 2016. Dr. Mandato has served on other public boards and continues to serve on the board of directors of several private companies and non-profit organizations.

Dr. Mandato has served as CEO of several successful operating companies, including two leveraged buyouts. The first, an ophthalmic implant company, was sold to a UK-based public company, and the second, a leveraged purchase from Johnson & Johnson, was subsequently acquired by a NYSE-listed company. Both transactions resulted in significant value creation for shareholders. He also advised the founders, was an active investor and was appointed to the Board of Directors of Align Technology, Inc. (NASDAQ: ALGN), developer of the Invisalign clear orthodontic appliance.

Earlier in his career, he served as President and CEO of Origin Medsystems, a developer of minimally invasive surgical devices, where he also co-founded and served as CEO of Gynecare, a women’s health spin-out from Origin, which was later acquired by Johnson & Johnson. Origin was acquired by Guidant Corporation (which was NYSE-listed prior to being acquired by Boston Scientific), where Dr. Mandato served as a Vice President and member of the founding management committee and CEO of two of its five operating units. He has also served as an Entrepreneur-in-Residence at Mayfield Fund, a venture capital firm.

Prior to his distinguished career, Dr. Mandato served as a Captain in the U.S. Army. He currently serves on the boards of Embrace Global and Save the Children. In 2004, Dr. Mandato received his doctorate degree in management from Case Western Reserve University, focusing his research on the evolving role of boards of directors in ensuring effective enterprise governance, and serves on its Board of Trustees. Dr. Mandato holds the Carlo Rossi Chair in Entrepreneurship and Management at the University of San Francisco, is a Lecturer at Stanford University and is currently a Fellow in the Harvard University Advanced Leadership Initiative.